Showing 4261-4270 of 9735 results for "".
- ISDIN Sunscreen Survey: Just 37% of the US Population Protects Themselves from the Sun on a Daily Basishttps://practicaldermatology.com/news/isdin-sunscreen-survey-just-37-of-the-us-population-protects-themselves-from-the-sun-on-a-daily-basis/2460505/While half of the US population is aware of the importance of sun protection and state they use sun protection during sun exposure, only 37 percent are using it on a daily basis, according to new survey from ISDIN. In the s
- AmorePacific Launches New Woke Skincare Brandhttps://practicaldermatology.com/news/amorepacific-launches-new-woke-skincare-brand/2460503/South Korea’s Amorepacific is launching its newest vegan-friendly lifestyle brand: Enough Project. This new brand is vegan-friendly, involves no animal testing, and contains no animal ingredients. In addition, Enough
- Third Pivotal Phase 3 Study Shows Rinvoq Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitishttps://practicaldermatology.com/news/third-pivotal-phase-3-study-shows-rinvoq-plus-topical-corticosteroids-improves-skin-and-itch-symptoms-in-atopic-dermatitis/2460489/AbbVie's upadacitinib (15 mg and 30 mg, once daily) (Rinvoq) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase 3 study of Rinvoq in atopic dermatitis. AD Up evaluated the efficacy and safety of both doses of upadaciti
- This Is Why Sarecycline Is So Effective Against Acnehttps://practicaldermatology.com/news/this-is-why-sarecycline-is-so-effective-against-acne/2460488/Researchers at Yale and the University of Illinois-Chicago have discovered how Sarecycline’s unique chemical structure makes it so effective against acne. Unlike other tetracycline drugs, sarecycline binds to messenger RNA (mRNA) in bacterial ribosomes. Sarecycline and other
- New York’s Mount Sinai Health System Names New Chair of Dermatology and New Dean For Clinical Therapeuticshttps://practicaldermatology.com/news/new-yorks-mount-sinai-health-system-names-new-chair-of-dermatology-and-new-dean-for-clinical-therapeutics/2460486/Emma Guttman-Yassky, MD, PhD, is the new Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System. She will be the first woman to serve as Chair of a Department of Dermatology in New York City. S
- Meet Amber Edwards, Alastin Skincare’s New Chief Commercial Officerhttps://practicaldermatology.com/news/meet-amber-edwards-alastin-skincares-new-chief-commercial-officer/2460485/Amber Edwards is Alastin Skincare’s new Chief Commercial Officer, effective July 31, 2020 Ms. Edwards most recently served as President of North America for Sinclair Pharma. Prior to Sinclair, she was at Allergan, Inc. where she was the Vice President of International Strategic Ma
- Bimekizumab Bests Cosentyx in Achieving Complete Psoriasis Skin Clearancehttps://practicaldermatology.com/news/bimekizumab-bests-cosentyx-in-achieving-complete-psoriasis-skin-clearance/2460478/UCB’s investigational IL-17A and IL-17F inhibitor bimekizumab outperformed the IL-17A inhibitor Cosentyx (secukinumab) in a head-to-head Phase 3 b study of adult patients with moderate-to-severe plaque psoriasis. This is the first head-to-head study comparing a
- Researchers Explore Nitric Oxide to Slow Progression of COVID-19https://practicaldermatology.com/news/industry-responds-to-covid-19-researchers-call-for-exploration-of-nitric-oxide-to-slow-progression-of-covid-19/2460477/George Washington University (GW) researchers urge renewed research of nitric oxide treatment as a potential tool to fight SARS-CoV-2, the coronavirus that causes COVID-19, in a review published in the journal Nitric Oxide. The authors suggest that if nitric oxide's efficacy is illustrat
- Abbvie's Rinvoq Monotherapy Meets All Primary and Secondary Endpoints in Second Phase 3 Study for Atopic Dermatitishttps://practicaldermatology.com/news/abbvies-rinvoq-monotherapy-meets-all-primary-and-secondary-endpoints-in-second-phase-3-study-for-atopic-dermatitis/2460475/AbbVie's upadacitinib (Rinvoq) (15 mg and 30 mg, once daily) monotherapy met both primary and all secondary endpoints in Measure Up 2, the second Phase 3 study in individuals with moderate to severe atopic dermatitis. The co-primary endpoints were at least a 75 percent improvement in the Ecze
- Skin of Color Update Goes Virtual for 2020https://practicaldermatology.com/news/skin-of-color-update-goes-virtual-for-2020/2460459/Skin of Color Update’s 2020 event is going virtual. The largest medical education event focused on the dermatologic treatment of skin of color will be held September 12-13. The Skin of Color Update agenda has been modified to reflect virtual learning. Live session